Several other brokerages have also recently commented on NH. BidaskClub raised shares of NantHealth from a sell rating to a hold rating in a research report on Tuesday, January 16th. Zacks Investment Research raised shares of NantHealth from a hold rating to a buy rating and set a $4.25 target price on the stock in a report on Thursday, January 11th. Finally, Cowen reissued a buy rating and issued a $4.50 target price on shares of NantHealth in a report on Tuesday, March 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $4.69.
Shares of NH stock traded down $0.09 during trading hours on Wednesday, hitting $3.01. 77,344 shares of the company were exchanged, compared to its average volume of 95,061. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.26 and a current ratio of 2.28. NantHealth has a one year low of $2.60 and a one year high of $5.26. The stock has a market capitalization of $336.60, a price-to-earnings ratio of -2.69 and a beta of 0.33.
NantHealth (NASDAQ:NH) last issued its quarterly earnings results on Wednesday, March 14th. The company reported ($0.21) EPS for the quarter. NantHealth had a negative return on equity of 54.16% and a negative net margin of 188.81%. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $23.50 million. research analysts forecast that NantHealth will post -0.61 EPS for the current year.
In other NantHealth news, COO Ronald Allen Louks sold 7,095 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $3.56, for a total value of $25,258.20. Following the transaction, the chief operating officer now owns 89,690 shares of the company’s stock, valued at $319,296.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 20,575 shares of company stock worth $66,108 in the last three months. 58.00% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in NH. Advisor Group Inc. acquired a new stake in shares of NantHealth in the fourth quarter valued at approximately $450,000. Millennium Management LLC acquired a new stake in shares of NantHealth in the fourth quarter valued at approximately $344,000. Dimensional Fund Advisors LP acquired a new stake in shares of NantHealth in the third quarter valued at approximately $365,000. Northern Trust Corp increased its stake in shares of NantHealth by 133.9% in the second quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after purchasing an additional 86,955 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of NantHealth by 20.2% during the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after acquiring an additional 71,087 shares during the period. Institutional investors own 6.25% of the company’s stock.
TRADEMARK VIOLATION WARNING: “NantHealth (NASDAQ:NH) Given a $5.00 Price Target by Jefferies Group Analysts” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/04/16/jefferies-group-analysts-give-nanthealth-nh-a-5-00-price-target.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.